Keywords: sits-most, results, confirm, actilyse, safety, treatment, ischemic
SITS-MOST results confirm Actilyse's safety as a treatment for ischemic stroke
Article | 05 February 2007
German drugmaker Boehringer Ingelheim says that data from SITS-MOST (Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy) confirm the safety of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
